• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»refractive surgery

Can ZEISS turn ophthalmology workflow software into the next battleground in cataract care?

By Pallavi Madhiraju on April 7, 2026   Medical Devices & Diagnostics  

Can ZEISS turn ophthalmology workflow software into the next battleground in cataract care?

ZEISS unveiled new AI, cataract planning, and cloud workflow tools at ASCRS 2026. Read what this means for ophthalmology practices.

STAAR Surgical advances EVO ICL adoption as FDA approval reframes high-myopia treatment economics

By Pallavi Madhiraju on February 19, 2026   Medical Devices & Diagnostics  

STAAR Surgical advances EVO ICL adoption as FDA approval reframes high-myopia treatment economics

FDA expands EVO ICL use to ages 21–60. Discover what this means for refractive surgery, safety data, and the shift away from laser vision correction.

Recent Posts

  • AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
  • Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
  • AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?
  • How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
  • What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
  • Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
  • What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
  • Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
  • Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
  • What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
  • Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
  • What SurGenTec’s TiLink navigation clearance means for surgeons using minimally invasive SI joint fusion systems
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes